Gene Solutions intergrates into the global scientific flow with ctDNA technology solutions for cancer

Gene Solutions – a representative from Vietnam – officially participated in the International Scientific Workshop ESMO ASIA 2023 held from December 1st to 3rd in Singapore.

Ranked among the world’s ‘research powerhouses,’ Singapore is also seen as an ideal launching pad to promote new technologies and foster international cooperation. However, scientific and commercial collaboration in Singapore is not easy due to its strict requirements and criteria for most products in circulation. Note only a challenge but also a great opportunity for many Vietnamese businesses to grow and expand globally.

This year, Gene Solutions is one of the new members participating in ESMO ASIA 2023 from Vietnam, representing the field of sequencing technology applications. Prior to this, the name Gene Solutions had achieved notable accomplishments with breakthrough research and high recognition, with 11 State-of-the-art Illumina and MGI platforms, 25.000+ NGS (Next-Generation Sequencing) based comprehensive gene panel testing, 40.000+ cancer screening tests, 1.000.000+ NGS genetic tests, 2.500+ Partners Southeast Asia, 40+ International Publications.

Thanks to efforts over the past many years, the company has grown six laboratories spreading across six countries in the region: Vietnam, Thailand, Indonesia, Malaysia, the Philippines, and Singapore. These centers all meet EMQN & ISO 15189:2012 standards. Particularly, the laboratory in Singapore is the evidence of cooperation and recognition from this global powerhouse.

Recently, Gene Solutions received 2 awards from the American Society of Clinical Oncology (ASCO Breakthrough Abstract Award, August 20213) and was selected as 1 of 4 outstanding studies at the conference to attend the press conference. In December 2023, Gene Solutions will continue the journey of introducing research results achieved at the European Society of Internal Medicine Oncology (ESMO Asia 2023) with 5 reports, including 1 oral report (oral presentation) and 4 poster reports. Among them, two poster report was awarded the Merit Award.

About ESMO, it is a highly influential oncology platform with significant professional contribution in the field due to the participation of experts, researchers, clinical doctors, and journalists representing global healthcare, especially for the Asia-Pacific region. ESMO ASIA 2023 in Singapore focuses on new technologies and solutions related to various types of cancer and related diseases. At the same time, it is an excellent networking opportunity for leading experts to meet, exchange, and share expertise.

Present at ESMO ASIA 2023, Gene Solutions hopes to introduce its significant achievements in Next-generation sequencing – NGS, providing a significant step forward in personalized medicine in cancer treatment. With products like SPOT-MAS, OncoGS, K-TRACK, K-4CARE, Gene Solutions has been at the forefront of applying cell-free DNA technology to support screening, diagnosis, guilding and monitoring treatment for various types of cancer.

It is known that to mark the first year of participating in ESMO ASIA 2023, Gene Solutions organizes an expert meeting with the theme “A One-stop solution to all cancer patients” on November 30th, with the participation of 50 doctors and experts from Asia.

With this effort, Gene Solutions expects to provide high-quality information and solutions, contributing to advancing cancer management through Next-generation sequencing (NGS).”

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More